Live Now: E-DICE-R (64/020,559) + MindNetQ (63/914,248) running end-to-end cancer biomarker workflows in the cloud — partner access now open.

Partner pricing

E-DICE-Edge Partner Vault —
own the governance layer.

Access our proprietary molecular governance technology through two interfaces. Pharma and biotech partners pay to use the method, system, and workflow we own.

Interface 01
E-DICE-Edge
Direct access to the governed multi-omics platform — authority scoring, validation gates, and audit workflows for your research team.
Interface 02
E-DICE-Edge Partner Vault
SDK-level integration — deploy the governance engine directly into your existing pharma or multi-omics pipelines. Real-time, shard-aware, audit-ready.
Live cloud deployment
Provisional patents filed
Method — proof of process
SPIE 2026 peer-reviewed
Pharma-pathway ready
Method
A governed pipeline for target discovery

Defined ingestion → authority scoring → validation gates → ranked output. You apply it to your data. We own the process.

System
Deterministic, auditable architecture

Every decision is logged. Every output is replayable. Full evidence chain maintained — results are defensible for downstream use.

Pharma Workflow
Structured outputs for drug development

Ranked candidates, structured evidence packages, and validation tracking — ready to plug into target selection and portfolio review workflows.

Pilot entry point

Start with a fixed-scope pilot. Scale when it proves value.

Before committing to an annual license, most partners begin with a scoped pilot. Governed outputs. Replayable results. A concrete example run for your team.

Early Access Pilot
$20K
6 weeks
  • Dataset onboarding
  • Governed multi-omics analysis
  • Candidate output review session
  • Final report with replayable results
Best for first engagement and proof of value.
Biotech Pilot
$25K–$75K
4–8 weeks
  • Multiple governed runs
  • Biomarker and pathway candidate ranking
  • Cross-cohort consistency analysis
  • Team review + pilot summary
For discovery teams validating governed candidate selection.
Pharma Exploratory
$75K–$150K
Custom scope
  • Custom workflow design
  • Collaborative validation support
  • Replayable outputs and reporting
  • Executive readout and roadmap
For larger exploratory programs and translational research teams.
Partner vault pricing

Six access paths. One governed platform.

Partners license our proprietary E-DICE-Edge technology to apply molecular governance, authority-based scoring, and reproducible decision workflows to their own datasets and drug pipelines.

Usage-based
$0.10–$1
per sample  ·  or $5K–$25K / cohort
Usage-Based
Pricing that scales with your data volume. Per-sample or per-cohort processing — ideal when throughput varies by program.
  • Per sample or cohort processing
  • Flexible scaling with data volume
  • Suitable for variable-throughput programs
When to use Scaling with data volume — variable research programs.
Add-on
+$100K–$300K
per module / year
Premium Modules
Advanced governance, audit, and regulatory packages layered on top of base access. Designed for regulated pharma environments.
  • Advanced governance packages
  • Audit and compliance modules
  • Regulatory-ready evidence packages
When to use Add-ons for pharma teams in regulated environments.
Per program
$250K–$1M
per program
Per-Program
Governance applied to a specific drug pipeline or target-discovery program. Structured evidence packages included.
  • Program-specific configuration
  • Workflow integration for target selection
  • Structured evidence packages for portfolio review
When to use Direct pharma workflows tied to a specific pipeline.
Full platform
$500K–$2M
per year
Enterprise License
Full platform plus pipeline integration for large pharma organizations with multi-team discovery programs.
  • Full platform access
  • Multi-team pipeline integration
  • Priority support and roadmap alignment
When to use Large pharma, multi-team, multi-program deployments.
Top tier
$2M–$10M
multi-year
Strategic Partnership
Co-development, deep integration, and shared-upside arrangements with top-tier pharma partners. Long-term strategic alignment.
  • Top-tier pharma co-development
  • Deep integration and roadmap alignment
  • Shared strategic development + upside
When to use Top-tier pharma, multi-year strategic partnerships.
Subscription paths

Deployment models for active programs.

Monthly subscription paths for teams with ongoing discovery workflows. Start with a fixed-scope pilot, then move to a subscription once the workflow proves value.

Starter
$5K–$10K
/mo
Limited governed runs for small research teams exploring the platform.
Pro
$15K–$40K
/mo
Full governed pipelines for active discovery programs with regular output cycles.
Enterprise
$50K+
/mo
Custom workflows, higher-touch support, and broader pipeline integration.
Two access interfaces

Choose your integration model.

Partners can access E-DICE-Edge technology through a direct platform interface or through the Partner Vault SDK for deep pipeline integration.

Interface 01
E-DICE-Edge
Direct, governed multi-omics discovery platform. Your team uses the interface to run discovery workflows, review ranked candidates, and access full audit trails.
  • Authority-based scoring on your datasets
  • Non-compensating validation gates
  • Deterministic, replayable outputs
  • Full evidence chain and audit log
  • Illustrative governed candidate run available
View invention details →
Interface 02
E-DICE-Edge Partner Vault
SDK-level deployment — integrate our molecular governance layer directly into your existing pharma or multi-omics pipelines. Real-time, shard-aware, and audit-ready at scale.
  • Deploy governance into your own pipeline
  • Apply authority scoring to your datasets
  • Reduce downstream validation risk
  • Generate audit-ready evidence packages
  • Suitable for top-tier pharma and enterprise organizations
Request partner access →
Ready to engage?

We own the method. Pharma pays to use it.

E-DICE-R defines a governed pipeline for identifying and prioritizing therapeutic targets. The method and system are filed as provisional patents — the pipeline is what we license. Contact us to discuss a pilot, partnership, or direct pharma engagement.

Contact George — LinkedIn Strategic Partner Pathway View invention position
Live cloud deployment
PRR36 p = 2.57×10⁻²¹
SPIE 2026 peer-reviewed
Method + System + Pharma claims filed